TransMedics Group

General Information


We are a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body.

Employees: 92
Founded: 1998
Contact Information
Address 200 Minuteman Road. Andover, MA 01810, US
Phone Number (978) 552-0900
Web Address
View Prospectus: TransMedics Group
Financial Information
Market Cap $323.8mil
Revenues $13.0 mil (last 12 months)
Net Income $-23.8 mil (last 12 months)
IPO Profile
Symbol TMDX
Exchange NASDAQ
Shares (millions): 5.7
Price range $16.00 - $16.00
Est. $ Volume $91.0 mil
Manager / Joint Managers Morgan Stanley/ J.P. Morgan
CO-Managers Cowen and Company/ Canaccord Genuity
Expected To Trade: 5/2/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change